Companies: 10,795·Total market cap: $144.5T
Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals, Inc.

MDGLNASDAQHealthcare● Active
$486.98
$-5.85(-1.19%)
Market Cap$11.2B
P/E Ratio
52W High$615
52W Low$271.96

Madrigal Pharmaceuticals, Inc. (MDGL) Stock Forecast & Analyst Price Target

Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.

mdgl · stock forecast · 23 analysts (3M) · FMP · updated Jun 8, 2026

Analyst Rating & Consensus

Based on 23 Wall Street analysts in the past 3 months

SellBuy

Buy

23 analysts

consensus

Rating Breakdown

Strong Buy
0
Buy
20
Hold
2
Sell
1
Strong Sell
0
Total: 23 · Buy rate: 87.0%

12-Month Price Target

High

$964

Consensus

$731

+50.2% upside

Low

$571

Median: $679 · Last Close: $486.98

The Madrigal Pharmaceuticals, Inc. (MDGL) analyst consensus is Buy, based on ratings from 23 Wall Street analysts over the past 3 months. The average 12-month MDGL price target is $731.25, representing +50.2% upside from the current price of $486.98.

12-Month Price Target Forecast

Historical closing prices + analyst 12-month price target forecast cone

Historical priceConsensus $731 (50.2%)

Consensus Target

$731.25

50.2% upside

High Target

$964

98.0%

Low Target

$571

17.3%

Current Price

$486.98

as of today

Based on analyst price targets, the MDGL stock price prediction for the next 12 months ranges from $571 to $964. The consensus MDGL price forecast of $731.25 implies 50.2% upside from the current price of $486.98.

Short-Term Price Prediction

Algorithmically generated · Updated daily

DatePredicted PriceChange
2026-06-09$469.653.56%

1-day model range: $467.05–$472.25. Peak: $472.25 (-3.56%).

Long-Term Stock Price Prediction

Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031

YearAvg PriceChange
2027$609+25.1%
2028$709+45.6%
2029$784+61.0%
2030$838+72.2%
2031+79.9%
Confidence:Medium

Stock Forecast Based on Technical Analysis

14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency

Market Sentiment

BEARISH

Based on 14 technical indicators

14%7%79%
2Buy
1Neutral
11Sell
RSI (14)37.6Neutral
MACDBEARISH

Refreshes daily from EOD close

Moving Averages · MDGL · Jun 8, 2026

Simple Moving Average (SMA)
MA 5$480.41BUY
MA 10$498.45SELL
MA 20$507.27SELL
MA 50$516.26SELL
MA 100$490.16SELL
MA 200$490.43SELL
Current $MDGL · Price above MA = BUY signal
Exponential Moving Average (EMA)
EMA 5$488.05SELL
EMA 10$494.57SELL
EMA 20$502.73SELL
EMA 50$504.77SELL
EMA 100$498.26SELL
EMA 200$471.88BUY
Current $MDGL · Price above MA = BUY signal
How we calculate: Technical sentiment is derived from 14 indicators — SMA(5,10,20,50,100,200), EMA(5,10,20,50,100,200), RSI(14), and MACD(12,26,9) — calculated from historical EOD price data. BUY = current price above MA; SELL = below. 14 TA signals + historical EOD price data · Updated daily. Independent of analyst consensus data. Not investment advice.

Latest Analyst Ratings & Upgrades

Filter:
Truist Securities2026-05-13
Maintains
BuyBuy
Evercore ISI Group2026-05-07
Maintains
OutperformOutperform
Canaccord Genuity2026-05-07
Maintains
BuyBuy
HC Wainwright & Co.2026-05-06
Maintains
BuyBuy
B of A Securities2026-02-20
Maintains
NeutralNeutral
Citizens2026-01-20
Maintains
Market OutperformMarket Outperform
Piper Sandler2025-12-19
Maintains
OverweightOverweight
B. Riley Securities2025-12-11
Maintains
BuyBuy
HC Wainwright & Co.2025-11-21
Maintains
BuyBuy
Oppenheimer2025-11-20
Maintains
OutperformOutperform

Wall Street analysts have recently issued updated ratings on Madrigal Pharmaceuticals, Inc. (MDGL) stock. Of the recent 115 rating actions, 8 were upgrades and 6 were downgrades. 23 analysts currently cover MDGL.

Analyst Recommendation Trends

Buy ratings24↑ +2
Hold ratings00
Sell ratings00

MDGL analyst recommendation trends show increasing buy-side sentiment over the past 6 months. Buy rating actions changed from 2 to 4 per month.

Financial Forecast: EPS & Revenue Estimates

Revenue This Year

$1.5B

↓ 50.2% YoY

Revenue Next Year

$2.2B

↑ 48.6% YoY

EPS This Year

$-6.55

EPS Next Year

$10.54

↓ 261.0% YoY

EPS ForecastReported vs Estimated

Reported EPSHistorical estimateAnalyst forecast (future)

Analysts forecast MDGL EPS of $-6.55 for the current fiscal year, based on estimates from 8 analysts. The MDGL revenue forecast is $1.5B for the current year. These are analyst consensus estimates via FMP / S&P Global.

About Forecast & Price Prediction

The MDGL stock forecast is supported by two independent data sources: analyst consensus ratings from 23 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus MDGL price target is $731.25 (+50.2% upside), with an analyst consensus of Buy.

The MDGL short-term stock prediction for tomorrow is $469.65 (-3.56%). The MDGL stock price prediction for 2027 estimates an average of $609. The MDGL stock prediction for 2030 projects a range of $788–$889.

Madrigal Pharmaceuticals, Inc. trades on NASDAQ under the ticker MDGL. The MDGL stock outlook for 2027 is broadly positive, supported by a Buy consensus among 87% of covering analysts.

FAQ answers synthesize analyst targets, estimates, and on-page model outputs where shown.

Frequently asked questions

MDGL forecast · 8 questions

According to 23 Wall Street analysts, the average 12-month MDGL price target is $731.25, with a high forecast of $964.00 and a low of $571.00. The median price target is shown in the chart above when available. This implies +50.2% potential upside from the current price of $486.98.

MDGL price targetWhat is MDGL price targetMDGL analyst price targetMDGL 12-month target

· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)

⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.